What is intestinal metaplasia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Intestinal Metaplasia?

Gastric intestinal metaplasia (GIM) is a precancerous condition where the normal gastric mucosal epithelial cells are replaced by intestinal-type epithelium, representing a critical step in the progression toward gastric adenocarcinoma. 1, 2

Pathophysiology and the Correa Cascade

GIM develops through a well-established stepwise progression model known as the Correa cascade, which describes the evolution from normal gastric epithelium → chronic inflammation → atrophic gastritis → intestinal metaplasia → dysplasia → invasive gastric cancer 3, 4. This transformation involves:

  • Loss of acid-pumping parietal cells in the setting of chronic inflammation
  • Metaplastic change in differentiation patterns where gastric cells acquire intestinal characteristics
  • Genetic and epigenetic alterations affecting key genes and signaling pathways 2, 5

The primary driver of this process is Helicobacter pylori infection, which is classified as an environmental metaplastic atrophic gastritis 6.

Histologic Subtypes and Cancer Risk

GIM is classified into two distinct histologic types with different malignant potential 1, 7:

Complete (Small Intestinal Type) Intestinal Metaplasia

  • Contains sucrase, trehalase, leucine aminopeptidase, alkaline phosphatase
  • Has goblet cells and Paneth cells
  • Goblet cells contain sialomucin (like small intestine)
  • Lower cancer risk

Incomplete (Colonic Type) Intestinal Metaplasia

  • Contains sucrase and leucine aminopeptidase but lacks trehalase and Paneth cells
  • Goblet cells contain sulphomucin and sialomucin (like large intestine)
  • 3.3-fold increased relative risk for gastric cancer 1
  • More closely associated with well-differentiated adenocarcinoma 7

Distribution and Risk Stratification

Extensive GIM carries higher cancer risk than limited disease 1:

  • Extensive GIM: Involves gastric body plus either antrum and/or incisura (2.1-fold increased RR)
  • Limited GIM: Involves only gastric antrum and/or incisura

Clinical Significance

GIM represents an approximate 0.16% annual risk and 1.6% ten-year cumulative risk for incident gastric cancer 1. However, this risk is substantially modified by:

  • Histologic subtype (incomplete vs complete)
  • Extent of involvement (extensive vs limited)
  • Family history of gastric cancer (4.5-fold increased RR) 1
  • Geographic/ethnic background (higher in immigrants from high-incidence regions) 6, 8

Key Clinical Caveat

GIM may persist or continue to progress even after H. pylori eradication, representing a potential "point of no return" in some patients 1. This underscores why surveillance may be necessary in high-risk individuals despite successful bacterial eradication.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.